ABOUT US
CHEMTEIOS Biologics is a biotechnology company based in Hong Kong that
is focused on developing the next generation of migrastatics. We have developed a concept known
as cancer-activated lectin multivalency, which has allowed us to generate protein therapeutics
capable of targeting metastatic cancer cells with unmatched selectivity.
While still relatively small in size, the CHEMTEIOS team is working tirelessly to push our current
developmental candidates into clinical trials, while also aggressively investigating other
candidates for effective against other cancer types for further development.
Kenward Vong, Ph.D.
Assistant Professor
HKUST
FOUNDER
Through his varied education and research experiences, Professor Kenward Vong has developed a keen desire to create protein therapeutics that can harness chemical principles and methodologies in new and creative ways. His research group at the Hong Kong University of Science and Technology is committed to this vision, which is where our LPAT technology was conceived and developed. Aiming to translate this breakthrough into potentially first-in-class preventative medicines, Prof Vong is wholly committed to leading this company to where it needs to be.